FDA grants Priority Review to Bayer’s sNDA for elinzanetant (Lynkuet) to treat moderate to severe vasomotor symptoms from endocrine therapy in breast cancer.

Endometriosis macrophenotypes exhibit distinct risk factor profiles and comorbidity patterns, suggesting varying disease etiologies.

The FDA has approved Bravnetsa (lutetium Lu 177 dotatate) via the ANDA pathway as a bioequivalent treatment option for SSTR-positive GEP-NETs.

IBD is not associated with increased risk for hypertensive disorders of pregnancy, but is associated with increased risk for preeclampsia.

Isolated diastolic hypertension in young adults is associated with an increased risk for atherosclerotic cardiovascular disease and heart failure.

Few women initiate systemic hormone therapy for menopausal symptoms, and the majority of patients who do discontinue treatment within the first year.

GLM101 received FDA Breakthrough Therapy designation for PMM2-CDG; primary endpoint data from the phase 2b POLAR trial evaluating ataxia via ICARS are expected in Q4 2026. The Food and Drug ...

The Endocrine Society successfully blocked an FTC subpoena regarding its gender-affirming care guidelines following a federal court injunction.

Deep-seated systemic and implicit racial biases within health care education, clinical decision-making, and diagnostic practices continue to drive persistent disparities in patient outcomes for people ...

Cardiovascular outcomes do not differ significantly by sex among patients receiving tirzepatide for obesity and heart failure.